Drugs / ATR-107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01162889 | Jun 2010 → Jan 2012 | — | Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATR-107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01162889 ↗ |
| Known as | PF-05230900 | “Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People” NCT01162889 ↗ |
| Route | Intravenous | “ATR-107 Administered Subcutaneously And Intravenously To Healthy Subjects” NCT01162889 ↗ |
| Route | Subcutaneous | “ATR-107 Administered Subcutaneously And Intravenously To Healthy Subjects” NCT01162889 ↗ |